Could Daily Aspirin Intake Prevent Colorectal Cancer?

The most common cause of hereditary colorectal (colon) cancer is Lynch Syndrome (“LS”). People with Lynch Syndrome have a 70% higher risk of developing colorectal cancer in their lifetime than the general population, and colorectal cancer is the leading cause of death among cancer cases in the U.S. Additionally, people with LS often develop colorectal cancer at much younger ages compared to the healthy population. However, there are no specific drugs that cure cancer, but following the set guidelines by the National Institute for Health and Care (“NICE”) in the UK, there may be some significant news. The information discussed below may offer a sigh of relief to the people suffering from colorectal cancer (“CRC”).

Clinical Trials by NICE

Recent clinical trials indicated that taking Aspirin for more than two years reduces the risk of colorectal cancer among people with Lynch Syndrome. In a clinical trial, only 4% of those who were taking daily Aspirin developed CRC as compared to the 7% under placebo group in a sample of 861 people with LS. However, adverse events did not vary significantly between the two groups. Furthermore, further studies are needed to establish the optimum dose and duration of daily Aspirin intake. It will also lead to more understanding of potential long-term effects.

Daily Benefits of Aspirin Might Outshine Harms Among People with Lynch Syndrome

The regular use of Aspirin among people with colorectal cancer and cardiovascular diseases has been a subject of discussion for decades. When Aspirin is used within the broader population, both the benefits and harms must be weighed in comparison. Some of the injuries, such as haemorrhagic stroke and gastrointestinal bleeding, must also be put into consideration. The available evidence is against the use of daily Aspirin, especially for people with average risk. However, for people with Lynch Syndrome, the benefits of using daily Aspirin supersedes the potential harms.

A Potential New Tier-1 Application

If the anticipated draft guidance becomes formalized, it will be the new CDC Tier-1 genomic guideline. Furthermore, it is expected to maintain most of the recommendations by NICE. The proposal has been defined as having a significant and positive impact on public health.

What Next for People with Lynch Syndrome?

For people with Lynch Syndrome, the NICE draft guidance provides an optimistic outlook towards their health. As the final NICE guidelines are on the verge of completion, patients with Lynch Syndrome can talk to health care workers about the ongoing clinical trials. People with Lynch Syndrome should encourage their relatives to go for earlier screenings and interventions because they have higher risks of contracting the disease. The earlier the interventions, the better as prevention is better than cure.

This news is likely to give Lynch Syndrome sufferers lots of hope, and it is such suffering people that keep companies like Predictive Oncology (NASDAQ: POAI) working hard to come up with breakthroughs that change lives.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.